Skip to content
Screener

Halozyme Therapeutics HALO Cash & Equivalents

Cash & Equivalents at other companies

West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
$435.8M-14.5%
AMP
Amphastar PharmaceuticalsAMPH
$223.61M+19.1%
AptarGroup logo
AptarGroupATR
$224.95M+78.8%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$127.64M+78.4%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
$110.73M+61.3%
TriSalus Life Sciences, Inc. logo
TriSalus Life Sciences, Inc.TLSI
$56.55M+324%

Other financials

Income statement

See full
Revenue$481.0M+47.7%
Gross profit$401.8M+43.8%
Operating income$287.7M+42.1%
Net income$229.9M+39.2%
EPS (diluted)$1.90+42.9%

Balance sheet

See full
Total debt$2.2B+41.6%
Total equity$143.5M-56.9%
Total assets$2.6B+25.5%

Cash flow

See full
Operating cash flow$240.9M+142%
CapEx$4.2M+167%
Free cash flow$236.7M+141%

Valuation

See full
Market cap$9.91B+36.0%
Enterprise value$11.93B+36.1%
P/E13.8×-3.9×
P/S6×-0.2×

Profitability

See full
Gross margin82.4%-1.8pp
Operating margin59.3%+9.0pp
Net margin47.9%+6.5pp
FCF margin48.5%+2.6pp

Returns & leverage

See full
Return on equity124.5%+12.7pp
Debt / equity15.2×+10.6×
Current ratio2.7×-5.7×

Where this comes from

Reported directly by Halozyme Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →

Filed
Aug 6, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001159036-26-000104

FAQ

What is Halozyme Therapeutics's cash & equivalents?
Halozyme Therapeutics (HALO) reported cash & equivalents of $163.99M in Q2 2026.
How has Halozyme Therapeutics's cash & equivalents changed year-over-year?
Halozyme Therapeutics's cash & equivalents increased by 165.1% year-over-year, from $61.86M to $163.99M.
What is the long-term trend for Halozyme Therapeutics's cash & equivalents?
Over 5 years (2020 to 2025), Halozyme Therapeutics's cash & equivalents has grown at a -1.6% compound annual growth rate (CAGR), from $148.2M to $136.42M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Halozyme Therapeutics's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude